var title_f4_17_4368="CT of depressed skull fracture";
var content_f4_17_4368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Depressed skull fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan showing a depressed skull fracture in the right frontal region (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4368=[""].join("\n");
var outline_f4_17_4368=null;
var title_f4_17_4369="Primary vitreoretinal lymphoma fundoscopy";
var content_f4_17_4369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fundoscopy of a patient with primary vitreoretinal lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are many small, round, yellow-orange lesions (arrows) at the retinal pigment epithelium level in the deep retina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chan CC, Rubenstein JL, Coupland, SE, et al. Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. Oncologist 2011; 16:1589. Copyright &copy; 2011 AlphaMed Press. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4369=[""].join("\n");
var outline_f4_17_4369=null;
var title_f4_17_4370="Calculator: Residual Renal Function in Hemodialysis Patients (Kru)";
var content_f4_17_4370=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"ResidualRenalFunction_form\" name=\"ResidualRenalFunction_form\" onkeydown=\"clrResults();\" onkeyup=\"ResidualRenalFunction_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Residual Renal Function in Hemodialysis Patients (Kru)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         MeanBUN = (U1 + U2) / 2",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         RRF = IDUrineVol * UrineUreaConc / IDPeriod / MeanBUN",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             ID Urine Vol",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"ID_Urine_Vol_param\" onblur=\"ResidualRenalFunction_fx(); minMaxCheck();\" onchange=\"ResidualRenalFunction_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"ID_Urine_Vol_unit\" onchange=\"ResidualRenalFunction_fx();\" style=\"width:105px;\">",
"             <option value=\"1000|0|L\">",
"              L",
"             </option>",
"             <option value=\"1e-12|0|fL\">",
"              fL",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mL\">",
"              mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Urine Urea Conc",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Urine_Urea_Conc_param\" onblur=\"ResidualRenalFunction_fx(); minMaxCheck();\" onchange=\"ResidualRenalFunction_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Urine_Urea_Conc_unit\" onchange=\"ResidualRenalFunction_fx();\" style=\"width:105px;\">",
"             <option value=\"100|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"1000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"0.001|0|mcg/dL\">",
"              mcg/dL",
"             </option>",
"             <option value=\"1|0|mg%\">",
"              mg%",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"100|0|mg/mL\">",
"              mg/mL",
"             </option>",
"             <option value=\"0.0001|0|ng/mL\">",
"              ng/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             ID Period",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"ID_Period_param\" onblur=\"ResidualRenalFunction_fx(); minMaxCheck();\" onchange=\"ResidualRenalFunction_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"ID_Period_unit\" onchange=\"ResidualRenalFunction_fx();\" style=\"width:105px;\">",
"             <option value=\"60|0|hr\">",
"              hr",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|min\">",
"              min",
"             </option>",
"             <option value=\"0.0166666666666667|0|sec\">",
"              sec",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             U1",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"U1_param\" onblur=\"ResidualRenalFunction_fx(); minMaxCheck();\" onchange=\"ResidualRenalFunction_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"U1_unit\" onchange=\"ResidualRenalFunction_fx();\" style=\"width:105px;\">",
"             <option value=\"100|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"1000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"0.001|0|mcg/dL\">",
"              mcg/dL",
"             </option>",
"             <option value=\"1|0|mg%\">",
"              mg%",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"100|0|mg/mL\">",
"              mg/mL",
"             </option>",
"             <option value=\"0.0001|0|ng/mL\">",
"              ng/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             U2",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"U2_param\" onblur=\"ResidualRenalFunction_fx(); minMaxCheck();\" onchange=\"ResidualRenalFunction_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"U2_unit\" onchange=\"ResidualRenalFunction_fx();\" style=\"width:105px;\">",
"             <option value=\"100|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"1000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"0.001|0|mcg/dL\">",
"              mcg/dL",
"             </option>",
"             <option value=\"1|0|mg%\">",
"              mg%",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"100|0|mg/mL\">",
"              mg/mL",
"             </option>",
"             <option value=\"0.0001|0|ng/mL\">",
"              ng/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Mean BUN",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Mean_BUN_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"Mean_BUN_unit\" onchange=\"ResidualRenalFunction_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"0.001|0|mcg/dL\">",
"               mcg/dL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"              <option value=\"0.0001|0|ng/mL\">",
"               ng/mL",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             RRF",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"RRF_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"RRF_unit\" onchange=\"ResidualRenalFunction_fx();\" style=\"width:105px;\">",
"              <option value=\"1000|0|L/min\">",
"               L/min",
"              </option>",
"              <option value=\"60000|0|L/sec\">",
"               L/sec",
"              </option>",
"              <option value=\"0.01666666667|0|mL/hr\">",
"               mL/hr",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mL/min\">",
"               mL/min",
"              </option>",
"              <option value=\"60|0|mL/sec\">",
"               mL/sec",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"ResidualRenalFunction_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      <b>",
"       U1",
"      </b>",
"      is the BUN just after the first dialysis of the week.",
"     </li>",
"     <li>",
"      <b>",
"       U2",
"      </b>",
"      is the BUN just prior to the second dialysis of the week.",
"     </li>",
"     <li>",
"      <b>",
"       ID",
"      </b>",
"      stands for Interdialytic period.",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Daugirdas JT, Ing TS.",
"       <i>",
"        Handbook of Dialysis",
"       </i>",
"       . Second Edition (1994) pp 92-107.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4370=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function ResidualRenalFunction_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.ResidualRenalFunction_form){",
"",
"",
"doCalc = true;",
"if (ID_Urine_Vol_param.value.indexOf(',') >= 0){ ID_Urine_Vol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(ID_Urine_Vol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = ID_Urine_Vol_unit.options[ID_Urine_Vol_unit.selectedIndex].value.split('|');",
"ID_Urine_Vol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Urine_Urea_Conc_param.value.indexOf(',') >= 0){ Urine_Urea_Conc_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Urine_Urea_Conc_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Urine_Urea_Conc_unit.options[Urine_Urea_Conc_unit.selectedIndex].value.split('|');",
"Urine_Urea_Conc = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (ID_Period_param.value.indexOf(',') >= 0){ ID_Period_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(ID_Period_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = ID_Period_unit.options[ID_Period_unit.selectedIndex].value.split('|');",
"ID_Period = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (U1_param.value.indexOf(',') >= 0){ U1_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(U1_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = U1_unit.options[U1_unit.selectedIndex].value.split('|');",
"U1 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (U2_param.value.indexOf(',') >= 0){ U2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(U2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = U2_unit.options[U2_unit.selectedIndex].value.split('|');",
"U2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Mean_BUN =  (U1 + U2) / 2;",
"",
"unit_parts = Mean_BUN_unit.options[Mean_BUN_unit.selectedIndex].value.split('|');",
"if (doCalc) Mean_BUN_param.value = fixDP((Mean_BUN - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"RRF =  ID_Urine_Vol * Urine_Urea_Conc / ID_Period / Mean_BUN;",
"",
"unit_parts = RRF_unit.options[RRF_unit.selectedIndex].value.split('|');",
"if (doCalc) RRF_param.value = fixDP((RRF - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.ResidualRenalFunction_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.ResidualRenalFunction_form){",
"",
"Mean_BUN_param.value = '';",
"RRF_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f4_17_4370=null;
var title_f4_17_4371="Lucinactant: Drug information";
var content_f4_17_4371=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lucinactant: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/2/2083?source=see_link\">",
"    see \"Lucinactant: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13855977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Lung Surfactant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14292498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/2/2083?source=see_link\">",
"      see \"Lucinactant: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Respiratory distress prophylaxis:",
"     </b>",
"     Premature infants: Endotracheal: 5.8 mL/kg  birth weight; up to 3 subsequent doses (total of 4 doses) may be administered at &ge;6-hour intervals within the first 48 hours of life.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16317805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16317806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14292483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13855974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Surfaxin&reg;: FDA approved March 2012; availability anticipated late 2012. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14292499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      For endotracheal administration only.",
"     </b>",
"     Prior to administration, the vial containing lucinactant must be properly warmed, followed by vigorous shaking until the suspension is uniform, free-flowing, and opaque white to off-white.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Slowly draw up the appropriate amount of lucinactant into a single, appropriately sized syringe (depending on total dose volume) using a 16- or 18-gauge needle. Administer endotracheally by instillation through a 5-French end-hole catheter inserted into the infant's endotracheal tube with infant properly positioned.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Administer the dose in 4 aliquots (each aliquot to be one-fourth of total volume). Each quarter-dose is instilled as a bolus followed by a pause to evaluate infant&rsquo;s respiratory status. Each quarter-dose is administered with the infant in a different position; slightly downward inclination with head turned to the right, then repeat with head turned to the left; then slightly upward inclination with head turned to the right, then repeat with head turned to the left. Following administration of one full dose, withhold suctioning for 1 hour unless signs of significant airway obstruction and keep infant&rsquo;s bed elevated &ge;10&deg; for 1-2 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13855979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14292488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Events observed during the dosing procedure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Endotracheal tube reflux (18% to 27%), endotracheal tube  obstruction (6% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Oxygen desaturation (8% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Cardiovascular: Bradycardia (3% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14292484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the FDA-approved labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14292485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Transient adverse effects: Transient episodes of bradycardia, decreased oxygen saturation, endotracheal tube blockage, or reflux of lucinactant into endotracheal tube may occur. Interrupt dosing procedure and initiate measures to stabilize infant's condition; may reinstitute after the patient is stable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Administration: For endotracheal administration only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Inappropriate use: In clinical trials of lucinactant in adults with acute respiratory distress syndrome (ARDS), an increased incidence of sepsis, pneumothorax, pulmonary embolism, hypotension, sepsis, and death was observed; therapy is not appropriate in the treatment of ARDS in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Monitoring: Produces rapid improvements in lung oxygenation and compliance that may require frequent adjustments to oxygen delivery and ventilator settings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Trained personnel: Rapidly affects oxygenation and lung compliance; restrict use to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14395095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14395093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14292501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following administration, patients should be carefully monitored so that oxygen therapy and ventilatory support can be modified in response to changes in respiratory status; frequent arterial blood gases are necessary to prevent postdosing hyperoxia and hypocarbia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14292494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Surfactant administration replaces deficient or ineffective endogenous lung surfactant in neonates at risk of developing RDS. Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between air and alveolar surfaces. Lucinactant, a synthetic surfactant containing phospholipids, also contains sinapultide (KL4 peptide) which resembles and is believed to mimic the action of one of the human surfactant proteins (SPs), namely SP-B.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Moya FR, Gadzinowski J, Bancalari E, et al, &ldquo;A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 115(4):1018-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4371/abstract-text/15805380/pubmed\" id=\"15805380\" target=\"_blank\">",
"        15805380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moya FR, Sinha S, Gadzinowski J, et al, &ldquo;One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119(6): e1361-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4371/abstract-text/17533176/pubmed\" id=\"17533176\" target=\"_blank\">",
"        17533176",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al, &ldquo;A Multicenter, Randomized, Controlled Trial of Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress Syndrome,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 115(4):1030-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4371/abstract-text/15805381/pubmed\" id=\"15805381\" target=\"_blank\">",
"        15805381",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83330 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4371=[""].join("\n");
var outline_f4_17_4371=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13855977\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292498\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317805\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317806\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292483\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13855974\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292499\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13855979\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292488\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292484\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292485\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14395095\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14395093\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292501\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292494\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83330|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/2/2083?source=related_link\">",
"      Lucinactant: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_17_4372="Skin biopsy lupus profundus I";
var content_f4_17_4372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus profundus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy of a patient with lupus profundus showing expansion of the interstices of the fat lobule with disintegrating leukocytes and fibrin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4372=[""].join("\n");
var outline_f4_17_4372=null;
var title_f4_17_4373="Lidocaine and prilocaine: Patient drug information";
var content_f4_17_4373=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lidocaine and prilocaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/25/32150?source=see_link\">",
"     see \"Lidocaine and prilocaine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/43/34486?source=see_link\">",
"     see \"Lidocaine and prilocaine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      EMLA&reg;;",
"     </li>",
"     <li>",
"      Oraqix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      EMLA&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691541",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pain from shots.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before dental care to numb the area.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lidocaine, prilocaine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cream:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cream:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on 1 hour before the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a rubber glove to put on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694424",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thick layer on the part where the shot is to be given. Do not rub in.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cover with a bandage or dressing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2964779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It will be put on you by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11780 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4373=[""].join("\n");
var outline_f4_17_4373=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188755\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188756\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023107\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023106\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023110\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023111\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023113\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023109\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023114\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023115\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/25/32150?source=related_link\">",
"      Lidocaine and prilocaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/43/34486?source=related_link\">",
"      Lidocaine and prilocaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_17_4374="Polyethylene glycol electrolyte solution: Drug information";
var content_f4_17_4374=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polyethylene glycol electrolyte solution: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34933?source=see_link\">",
"    see \"Polyethylene glycol electrolyte solution: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/38/25189?source=see_link\">",
"    see \"Polyethylene glycol electrolyte solution: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colyte&reg;;",
"     </li>",
"     <li>",
"      GaviLyte&trade;-C;",
"     </li>",
"     <li>",
"      GaviLyte&trade;-G;",
"     </li>",
"     <li>",
"      GaviLyte&trade;-N;",
"     </li>",
"     <li>",
"      GoLYTELY&reg;;",
"     </li>",
"     <li>",
"      MoviPrep&reg;;",
"     </li>",
"     <li>",
"      NuLYTELY&reg;;",
"     </li>",
"     <li>",
"      TriLyte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Colyte&trade;;",
"     </li>",
"     <li>",
"      Klean-Prep&reg;;",
"     </li>",
"     <li>",
"      PegLyte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Laxative, Osmotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bowel cleansing prior to GI exam:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CoLyte&reg;, GaviLyte&trade;-C, GaviLyte&trade;-G, GaviLyte&trade;-N, GoLYTELY&reg;, NuLYTELY&reg;, TriLyte&reg;: 240 mL (8 oz) every 10 minutes, until 4 L are consumed or the rectal effluent is clear; rapid drinking of each portion is preferred to drinking small amounts continuously.",
"     <b>",
"      Note:",
"     </b>",
"     The solution may be given via nasogastric tube to patients who are unwilling or unable to drink the solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     MoviPrep&reg;: Administer 2 L total with an additional 1 L of clear fluid prior to colonoscopy as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Split dose: Evening before colonoscopy: 240 mL (8 oz) every 15 minutes until 1 L is consumed. Then drink 16 oz of clear liquid. On the morning of the colonoscopy, repeat process with second liter over 1 hour and then drink 16 oz of clear liquid at least 1 hour before the procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Full dose: Evening before colonoscopy (~6 PM): 240 mL (8 oz every 15 minutes) until 1 L is consumed; 90 minutes later (~7:30 PM), repeat dose. Then drink 32 oz of clear liquid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nasogastric tube:",
"     </i>",
"     20-30 mL/minute (1.2-1.8 L/hour); the first bowel movement should occur ~1 hour after the start of administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Toxic ingestion (unlabeled use; AACT, 2004):",
"     </b>",
"     <i>",
"      Nasogastric tube:",
"     </i>",
"     1500-2000 mL/hour until rectal effluent is clear.",
"     <b>",
"      Note:",
"     </b>",
"     May take several hours for the rectal effluent to become clear. Duration may be extended if evidence of continued presence of toxins in GI tract (eg, radiographic evidence or ongoing elimination of toxins)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F211134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/38/25189?source=see_link\">",
"      see \"Polyethylene glycol electrolyte solution: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bowel cleansing prior to GI exam:",
"     </b>",
"     Children &ge;6 months (GaviLyte&trade;-N, NuLYTELY&reg;, TriLyte&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     25 mL/kg/hour (some studies have used up to 40 mL/kg/hour) for 4-10 hours until rectal effluent is clear (maximum total dose: 4 L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nasogastric tube:",
"     </i>",
"     25 mL/kg/hour until rectal effluent is clear",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Toxic ingestion (unlabeled use; AACT, 2004):",
"     </b>",
"     <i>",
"      Nasogastric tube:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;9 months to 6 years: 500 mL/hour until rectal effluent is clear",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: 1000 mL/hour until rectal effluent is clear",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: 1500-2000 mL/hour until rectal effluent is clear",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     May take several hours for the rectal effluent to become clear. Duration may be extended if evidence of continued presence of toxins in GI tract (eg, radiographic evidence or ongoing elimination of toxins)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for solution, oral: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL); PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL); PEG 3350 240 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colyte&reg;: PEG 3350 227.1 g, sodium sulfate 21.5 g, sodium bicarbonate 6.36 g, sodium chloride 5.53 g, and potassium chloride 2.82 g (3785 mL) [supplied with cherry, lemon lime, and orange flavor packs]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colyte&reg;: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL) [supplied with cherry, citrus berry, lemon lime, orange, and pineapple flavor packs]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GaviLyte&trade;-C: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL) [supplied with lemon flavor packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GaviLyte&trade;-G: PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL) [supplied with lemon flavor packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GaviLyte&trade;-N: PEG 3350 420 g,  sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with lemon flavor packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GoLYTELY&reg;: PEG 3350 227.1 g, sodium sulfate 21.5 g, sodium bicarbonate 6.36 g, sodium chloride 5.53 g, and potassium chloride 2.82 g per packet (1s) [regular flavor; makes 1 gallon of solution after mixing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GoLYTELY&reg;: PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL) [regular and pineapple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MoviPrep&reg;: Pouch A: PEG 3350 100g, sodium sulfate 7.5 g, sodium chloride 2.69 g, potassium chloride 1.02 g; Pouch B: Ascorbic acid 4.7 g, sodium ascorbate 5.9 g (1000 mL) [contains phenylalanine 131 mg/treatment; lemon flavor; packaged with 2 of Pouch A and 2 of Pouch B in carton and a disposable reconstitution container]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NuLYTELY&reg;: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with cherry, lemon-lime, orange, and pineapple flavor packs]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TriLyte&reg;: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with cherry, citrus berry, lemon lime, orange, and pineapple flavor packs]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12808915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     MoviPrep&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM253840.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM253840.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Rapid drinking of each portion is preferred to drinking small amounts continuously. Do not add flavorings, unless provided by the manufacturer, as additional ingredients before use. Chilled solution often more palatable. Oral medications should not be administered within 1 hour of start of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bowel cleansing prior to GI examination",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5949326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Whole bowel irrigation (WBI) in the following toxic ingestions: Packets of illicit drugs (body packers, body stuffers), potentially toxic sustained-release or enteric-coated agents, substantial amounts of iron (AACT, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F211145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       GoLYTELY&reg; may be confused with NuLYTELY&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TriLyte&reg; may be confused with TriLipix&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Malaise (18% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension (&lt;60%), anal irritation (&lt;52%), nausea (14% to 47%), abdominal pain (13% to 39%), vomiting (7% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Rigors (34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Thirst (&lt;47%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (7%), headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency  not defined, postmarketing, and/or case reports: Abdominal cramps, abdominal fullness, allergic reactions, anaphylaxis, aspiration, asystole, bloating, chest tightness, dehydration, dermatitis, dyspnea (acute), esophageal perforation, facial edema, fever, flatulence, hypersensitivity reactions, hypokalemia (children), Mallory-Weiss tear, pulmonary edema, rash, rhinorrhea, seizure, shock, throat tightness, upper GI bleeding, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to polyethylene glycol or any component of the formulation; ileus,  gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Seizures associated with electrolyte abnormalities (eg, hyponatremia, hypokalemia) have occurred. Use with caution in patients with underlying hyponatremia or with concomitant administration of medications that alter electrolyte balance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Observe unconscious or semiconscious patients with impaired gag reflex or those who are otherwise prone to regurgitation or aspiration during administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with severe ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MoviPrep&reg;: May be safer to use in patients who cannot tolerate fluid load (eg, heart failure, renal insufficiency, ascites); not  significantly absorbed. Use cautiously in patients with G6PD deficiency; contains ascorbic acid. Contains phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Evaluate patients with symptoms of bowel obstruction (nausea, vomiting, abdominal pain or distension) prior to use. Do not add flavorings, unless provided by the manufacturer, as additional ingredients before use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F211113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted in animals or in humans.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F211130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F211114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Significant changes in the mother's fluid or electrolyte balance would not be expected.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F211115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CoLyte&reg;, GaviLyte&trade;-C, GaviLyte&trade;-G, GaviLyte&trade;-N, GoLYTELY&reg;, NuLYTELY&reg;, TriLyte&reg;: Ideally, the patient should fast for ~3-4 hours prior to administration, but in no case should solid food be given for at least 2 hours before the solution is given. Some products contain aspartame which is metabolized to phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MoviPrep&reg;: Patient should not eat solid food from start of solution administration until after colonoscopy. Patient may have clear liquid soup/plain yogurt for dinner; finish at least 1 hour before start of colon prep. MoviPrep&reg; contains phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4589209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Colyte with Flavor Packs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     227.1 g (3785 mL): $45.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 g (4000 mL): $46.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (GaviLyte-C Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 g (4000 mL): $19.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (GaviLyte-G Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     236 g (4000 mL): $21.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (GaviLyte-N with Flavor Pack Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 g (4000 mL): $25.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Golytely Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     227.1 g (1): $15.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     236 g (4000 mL): $23.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (MoviPrep Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 g (1): $81.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Nulytely with Flavor Packs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 g (4000 mL): $32.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (PEG 3350-KCl-Na Bicarb-NaCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 g (4000 mL): $22.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (TriLyte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 g (4000 mL): $28.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F211102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Electrolytes, serum glucose, BUN, urine osmolality; children &lt;2 years of age should be monitored for hypoglycemia, dehydration, hypokalemia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F211093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induces catharsis by strong electrolyte and osmotic effects",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F211109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of effect: Oral: ~1-2 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Clinical Toxicology, European Association of Poison Centres and Clinical Toxicologists, &ldquo;Position Paper: Whole Bowel Irrigation,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2004, 42(6):843-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4374/abstract-text/15533024/pubmed\" id=\"15533024\" target=\"_blank\">",
"        15533024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chattopadhyay A, Prakash B, Vepakomma D, et al, &ldquo;A Prospective Comparison of Two Regimes of Bowel Preparation for Pediatric Colorectal Procedures: Normal Saline With Added Potassium vs Polyethylene Glycol,&rdquo;",
"      <i>",
"       Pediatr Surg Int",
"      </i>",
"      , 2004, 20(2):127-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4374/abstract-text/14752676/pubmed\" id=\"14752676\" target=\"_blank\">",
"        14752676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harris CR and Kingston R, &ldquo;Gastrointestinal Decontamination, Which Method Is Best?&rdquo;",
"      <i>",
"       Postgrad Med",
"      </i>",
"      , 1992, 92(2):116-22, 125, 128.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4374/abstract-text/1353876/pubmed\" id=\"1353876\" target=\"_blank\">",
"        1353876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olsen KM, Gurley BJ, Davis GA, et al, &ldquo;Comparison of Fluid Volumes With Whole Bowel Irrigation in a Simulated Overdose of Ibuprofen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(3):246-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4374/abstract-text/7606068/pubmed\" id=\"7606068\" target=\"_blank\">",
"        7606068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Porter RS and Baker EB, &ldquo;Drug Clearance by Diarrhea Induction,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1985, 3(3):182-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4374/abstract-text/3994793/pubmed\" id=\"3994793\" target=\"_blank\">",
"        3994793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scharman EJ, Lembersky R, and Krenzelok EP, &ldquo;Efficiency of Whole Bowel Irrigation With and Without Metoclopramide Pretreatment,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1994, 12(3):302-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4374/abstract-text/8179735/pubmed\" id=\"8179735\" target=\"_blank\">",
"        8179735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sondheimer JM, Sokol RJ, Taylor SF, et al, &ldquo;Safety, Efficacy and Tolerance of Intestinal Lavage in Pediatric Patients Undergoing Diagnostic Colonoscopy,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 119(1):148-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4374/abstract-text/2066847/pubmed\" id=\"2066847\" target=\"_blank\">",
"        2066847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tuggle DW, Hoelzer DJ, Tunell WP, et al, &ldquo;The Safety and Cost-Effectiveness of Polyethylene Glycol Electrolyte Solution Bowel Preparation in Infants and Children,&rdquo;",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 1987, 22(6):513-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/17/4374/abstract-text/3112357/pubmed\" id=\"3112357\" target=\"_blank\">",
"        3112357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woolf A and Pearson K, &ldquo;Presence of Diethylene Glycol in Commercial Polyethylene Glycol (PEG) Solutions,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(5):490.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9789 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-714CE7359B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4374=[""].join("\n");
var outline_f4_17_4374=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211122\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211123\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211139\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211125\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211134\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211126\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211104\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211090\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808915\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211107\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211105\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5949326\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211145\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211137\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211110\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211094\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299900\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222413\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211100\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211113\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211130\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211114\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211115\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589209\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211102\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211093\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211109\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9789\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9789|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34933?source=related_link\">",
"      Polyethylene glycol electrolyte solution: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/38/25189?source=related_link\">",
"      Polyethylene glycol electrolyte solution: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_17_4375="Congenital HSV 1";
var content_f4_17_4375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital herpes simplex viral disease-1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Congenital herpes simplex viral disease with wedge shaped involvement of the adrenal cortex in a markedly autolyzed 28 week fetus. Calcified infarcts in this region are nearly pathognomotic for herpes infection, which mostly go clinically unsuspected and silent in the mother.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4375=[""].join("\n");
var outline_f4_17_4375=null;
var title_f4_17_4376="Initial evaluation and management of rib fractures";
var content_f4_17_4376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial evaluation and management of rib fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/17/4376/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/17/4376/contributors\">",
"     Kristine A Karlson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/17/4376/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/17/4376/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/17/4376/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/17/4376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/17/4376/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/17/4376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rib fractures are common injuries, which occur most often following blunt thoracic trauma but can also result from severe coughing, athletic activities (eg, rowing, swinging golf clubs), and nonaccidental trauma (ie, child abuse). Concomitant injuries and complications range from mild discomfort to life-threatening conditions, such as pneumothorax, splenic laceration, and pneumonia.",
"   </p>",
"   <p>",
"    This topic will review the evaluation and management of rib fractures, including stress fractures. Discussions of the in-patient management of multiple rib fractures, blunt and penetrating thoracic trauma, and of stress fractures are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link\">",
"     \"Inpatient management of traumatic rib fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest wall consists of 12 pairs of ribs, the first seven of which articulate both posteriorly with the spine and anteriorly with the sternum (",
"    <a class=\"graphic graphic_figure graphicRef80627 \" href=\"UTD.htm?18/39/19064\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58842 \" href=\"UTD.htm?17/7/17528\">",
"     figure 2",
"    </a>",
"    ). Ribs 8 to 10 attach anteriorly to the costal cartilage. The lowest two ribs are \"floating\" and do not connect anteriorly [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/1\">",
"     1",
"    </a>",
"    ]. Immediately below each rib travels its neurovascular bundle, including the intercostal vein, artery, and nerve.",
"   </p>",
"   <p>",
"    The first rib is unique in that the scaleni insert onto it, and it therefore is exposed to stresses from the action of these neck muscles. The superior ribs (numbers 1 to 3) are relatively protected by the scapula, clavicle, and soft tissue, while the inferior \"floating\" ribs are relatively mobile. Therefore, the more vulnerable middle ribs (numbers 4 to 10) are most susceptible to injury from blunt trauma. Fractures of superior ribs reflect trauma involving significant force and the potential for injury to major vessels and lung parenchyma.",
"   </p>",
"   <p>",
"    The ribs act as a unit during respiration, moving in the anterior-posterior (AP) and coronal planes. This concerted rib motion, in addition to the actions of the diaphragm and the intercostal muscles, enables inspiration (by increasing intrathoracic volume and decreasing intrathoracic pressure) and expiration (by decreasing intrathoracic volume and increasing intrathoracic pressure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most rib fractures are caused by direct trauma to the chest wall. This can occur from blunt (eg, motor vehicle crash) or penetrating (eg, gunshot) trauma. A single blow may cause rib fractures in multiple places. Traumatic fractures most often occur at the site of impact or the posterolateral bend, where the rib is weakest. Both displaced and nondisplaced fractures can be seen in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/2\">",
"     2",
"    </a>",
"    ]. Due to the greater pliability of children's ribs, greater force is required to produce a fracture.",
"   </p>",
"   <p>",
"    Rib fractures may be pathologic. Cancers that metastasize to bone (eg, prostate, breast, renal) frequently become apparent in a rib. Ribs are relatively thin compared with major long bones and are more likely to fracture when invaded by a metastatic lesion.",
"   </p>",
"   <p>",
"    In the absence of significant trauma (eg, motor vehicle collision), rib fractures in infants are extremely uncommon. Clinicians must investigate possible nonaccidental trauma (ie, child abuse) when such fractures are discovered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H17#H17\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Thoracic injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ribs can sustain stress fractures from repetitive minor trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Stress fractures are seen in patients with severe cough [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], but also in athletes, particularly rowers and golfers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/5,8-11\">",
"     5,8-11",
"    </a>",
"    ]. Because of the unique forces exerted on the first rib, it is susceptible to stress fractures in throwing athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Relevant anatomy and physiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rib fractures who are not victims of high-energy trauma typically describe a history of minor or moderate blunt trauma to the chest wall. Often, they can localize the pain to one or two ribs, and they describe an injury that corresponds with the area of discomfort. The patient can frequently reproduce or exacerbate the pain by taking a deep breath.",
"   </p>",
"   <p>",
"    Examination findings strongly suggestive of rib fracture include severe point tenderness on a specific rib or focal tenderness caused by compression of the ribcage distant from the site of pain. Bony crepitance and ecchymosis may be present. Bony crepitance is an auscultated click caused by movement of the rib fracture and can be heard with a stethoscope placed over the fracture site.",
"   </p>",
"   <p>",
"    Clinicians should look, listen, and palpate for evidence of internal injury when examining patients with suspected rib fractures. Signs, such as diminished breath sounds, may reflect splinting from the pain of a simple chest wall contusion. However, they may also reflect the presence of significant injury (eg, pneumothorax or pulmonary contusion). Pneumothorax would present as diminished breath sounds and possibly air crepitance. Pulmonary contusion may cause diminished breath sounds, but if there is blood in the alveoli, crackles may be audible.",
"   </p>",
"   <p>",
"    Rib fractures sustained by patients as a result of more serious trauma are often associated with internal injury. Fractures of ribs 9 through 12 may be associated with intraabdominal injury; fractures of ribs 1, 2, or 3 may be associated with mediastinal injury, particularly to the aorta. Intrathoracic injury, such as pneumothorax or pulmonary contusion, can occur in association with rib fractures at any level. The risk of intraabdominal or intrathoracic injury increases if two or more rib fractures are present at the same level [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Fractures of the right lower ribs are more often associated with hepatic injury, fractures of the left lower ribs with splenic injury, and fractures of the posterior portion of the lower ribs with renal injury. The assessment of patients with high-energy abdominal or thoracic trauma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flail chest occurs when three or more adjacent ribs are each fractured in two places, creating one floating segment comprised of several rib sections and the soft tissues between them (",
"    <a class=\"graphic graphic_figure graphicRef79746 \" href=\"UTD.htm?23/19/23857\">",
"     figure 3",
"    </a>",
"    ). This unstable section of chest wall exhibits paradoxical motion (ie, it moves in the opposite direction of uninjured, normal-functioning chest wall) with breathing and is often associated with significant morbidity from pulmonary contusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link&amp;anchor=H1068084913#H1068084913\">",
"     \"Inpatient management of traumatic rib fractures\", section on 'Flail chest'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have impaired consciousness or are victims of high-energy trauma may be unable to localize pain to the chest wall. Clinicians often detect rib fractures in such patients by careful examination of the chest wall and back. In most victims of major trauma, a chest x-ray is obtained in the emergency department and is the means by which multiple or displaced rib fractures are identified [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/16\">",
"     16",
"    </a>",
"    ]. Although the practice of obtaining chest x-rays in all trauma victims has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/17\">",
"     17",
"    </a>",
"    ], it remains standard practice. Its role in this setting may be more important for finding associated trauma, such as hemothorax or pneumothorax rather than rib fractures. Nondisplaced rib fractures and those at the costochondral margin are often missed on plain chest x-ray. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Radiographs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stress fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rib stress fractures present with a gradual onset of activity-related chest wall pain, similar to stress fractures of other bones. Often the pain first occurs only with the inciting activity (eg, coughing, rowing, swinging a golf club), then progresses to pain with deep breathing or simple movements, such as rolling over in bed or reaching overhead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RADIOGRAPHS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging following trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard posterior-anterior (PA) and lateral chest radiographs are adequate to identify most rib fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83500 \" href=\"UTD.htm?24/14/24803\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83501 \" href=\"UTD.htm?21/55/22385\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83571 \" href=\"UTD.htm?32/28/33217\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/16\">",
"     16",
"    </a>",
"    ]. In patients who cannot undergo a PA and lateral radiograph (eg, those with hemodynamic instability or spinal immobilization), an anterior-posterior (AP) radiograph will often suffice. Chest x-rays enable clinicians to look for a pneumothorax, hemothorax, and other signs of intrathoracic injury, which is the main reason they are obtained. In patients who have sustained significant trauma to the torso, but do not require admission and will not be studied with a thoracic CT scan, we suggest a follow-up PA and lateral chest x-ray be performed six hours after initial presentation to rule out a delayed pneumothorax or hemothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of dedicated rib films for rib fracture is greater because these radiographs use a bone exposure and include oblique views of the chest wall not included on a standard chest series. In the great majority of cases, clinicians can base their diagnosis and management on plain radiographs and clinical findings, and a rib series is unnecessary. We suggest obtaining a rib series only if there is high clinical suspicion for pathologic or multiple rib fractures not apparent on plain chest x-ray, and detection of additional fractures would alter management. Clinicians should have a lower threshold for obtaining a rib series, or other imaging in elderly patients who have significantly increased morbidity from multiple rib fractures and are more likely to have pathologic fractures (eg, from metastatic lesions) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rib series is rarely obtained in trauma patients. Those patients suspected of having sustained a significant intrathoracic injury are evaluated with a CT scan of the chest (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83646 \" href=\"UTD.htm?17/37/18006\">",
"     image 4",
"    </a>",
"    ). CT is invaluable for identifying intrathoracic injuries and demonstrates greater sensitivity and specificity for rib fractures compared with plain radiographs. However, the initial screening plain chest x-ray obtained in trauma patients remains a useful tool, and injuries of sufficient magnitude to appear on the screening x-ray may predict subsequent pulmonary morbidity more accurately than CT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/24\">",
"     24",
"    </a>",
"    ]. Rib fractures of the lower rib cage can be associated with intraabdominal injury and abdominal CT may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/25\">",
"     25",
"    </a>",
"    ]. The evaluation of patients with possible intrathoracic injury is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, routine arteriography was recommended for patients with fractures of the first or second rib out of concern for aortic and other mediastinal injury. However, this approach is no longer recommended in the absence of evidence of vascular injury, such as a widened mediastinum on chest x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound may serve as a tool to distinguish between pathologic and traumatic fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/27\">",
"     27",
"    </a>",
"    ]. Some studies suggest ultrasound may be useful in the diagnosis of traumatic rib fractures, but further study is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should obtain a skeletal survey in infants suspected of being abused. Findings consistent with abuse include the presence of multiple rib fractures in various stages of healing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H17#H17\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Thoracic injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging stress fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special imaging may be required in some cases of suspected rib stress fracture when there is doubt about the diagnosis or when a definitive diagnosis is required to make decisions about returning to competition. A bone scan of the chest wall is the preferred instrument to diagnose rib stress fractures early in the pathologic process (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73877 \" href=\"UTD.htm?24/41/25246\">",
"     image 5",
"    </a>",
"    ). Such fractures typically are not visible on plain films of the chest until very late in their healing, when they develop a visible callus. The need for imaging will vary based on the clinician's experience managing rib stress fractures.",
"   </p>",
"   <p>",
"    While MRI is the imaging modality of choice for many types of stress fractures, bone scan is preferred for stress fractures of the ribs, if additional imaging is necessary. This is because the oblique orientation of the ribs and the difficulty with numbering them on axial or coronal scanning can make MRI more difficult to interpret. In addition, the detailed imaging of adjacent soft tissues provided by MRI is of lesser importance with rib fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent referral is generally needed because of the injuries that accompany rib fractures. Pneumothorax, liver and spleen lacerations, and pulmonary and cardiac contusions comprise some of the more serious injuries associated with rib fractures sustained in high-energy trauma. Pneumomediastinum and pneumopericardium suggest the presence of major injury. Fractures of the first three ribs generally occur from significant force and may be associated with mediastinal, particularly aortic, injury. Displaced rib fractures likely increase the risk of injury to the lung and proximate intercostal blood vessels.",
"   </p>",
"   <p>",
"    All patients with superior or displaced rib fractures, fractures of multiple ribs, or possible internal injuries should be sent directly to the emergency department (ED) for evaluation. Once in the ED, patients who have sustained significant trauma are managed in the appropriate manner, including imaging studies. Disposition is based upon the injuries identified, the risk of delayed presentation of significant injuries (eg, pulmonary contusion, intercostal bleeding), and clinical and social circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Disposition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Analgesia and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once significant associated injuries have been evaluated and treated, the cornerstone of rib fracture management is pain control [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Early and adequate pain relief is essential to avoid complications from splinting and atelectasis, primarily pneumonia. The choice of analgesia depends upon the injury, the clinician's comfort performing nerve blocks with their potential complications, and the ease with which more invasive treatments can be performed. Analgesia for severe and multiple rib fractures and monitoring of admitted patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link&amp;anchor=H1068084984#H1068084984\">",
"     \"Inpatient management of traumatic rib fractures\", section on 'Pain management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link&amp;anchor=H1068084976#H1068084976\">",
"     \"Inpatient management of traumatic rib fractures\", section on 'General management issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For isolated injuries (ie, single rib fracture), clinicians generally begin treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) with or without opioids. For more severe injuries, particularly if ventilation is compromised, admission and invasive treatments, such as intercostal nerve blocks, may be needed.",
"   </p>",
"   <p>",
"    Respiratory care, including use of incentive spirometry to prevent atelectasis and its complications, is often important. We do not recommend rib belts or binders because they compromise respiratory function. Studies of rib belts involve small numbers of patients and have reached contradictory conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Patients with a rib fracture who are discharged home can also use incentive spirometry throughout the day, after analgesics have taken effect. Holding a pillow or similar soft brace against the fracture site reduces discomfort while using the spirometer, or when coughing. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several researchers recommend hospital admission for any patient with three or more rib fractures, and ICU care for elderly patients with six or more rib fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. They cite the significant correlation between these findings and serious internal injuries, such as pneumothorax and pulmonary contusion. We suggest hospitalization for the majority of patients with three or more rib fractures. Patients with multiple rib fractures sustained from high-energy trauma are best evaluated at a trauma center. Transfer should be arranged expeditiously.",
"   </p>",
"   <p>",
"    Displaced rib fractures likely increase the risk of injury to the lung and proximate intercostal blood vessels. Bleeding from such fractures can be delayed, and admission or close observation and follow-up should be arranged for patients with displaced fractures, depending upon clinical and social circumstances. Multiple case reports indicate that delayed bleeding from intercostal vessels or other injuries can be life-threatening, particularly in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/19,35,36\">",
"     19,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical fixation may be of benefit with some types of rib fractures, particularly those associated with chest wall deformity, flail chest, or symptomatic nonunion. The appropriate role of surgical fixation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link&amp;anchor=H68784637#H68784637\">",
"     \"Inpatient management of traumatic rib fractures\", section on 'Surgical management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, younger healthy individuals with three rib fractures, having undergone a thorough clinical and radiographic evaluation by clinicians experienced in trauma management, and an appropriate period of observation (a minimum of six hours of observation, including a follow-up chest radiograph, is needed to rule out pneumothorax), may be discharged from the emergency department. Clinicians must also consider patient comorbidities and clinical and social circumstances when determining disposition. Patients with one or possibly two isolated rib fractures and no complicating factors may be discharged home with appropriate follow-up and adequate analgesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment of stress fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rib stress fractures are treated similarly to other low-risk stress fractures. Treatment begins with restriction of the inciting activity for four to six weeks, followed by a gradual return to the activity as tolerated. During rehabilitation, attention should be paid to proper biomechanics and elimination of training errors to avoid recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management and follow-up for patients with multiple rib fractures or rib fractures associated with significant internal injuries is discussed separately. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Disposition'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed injuries from isolated rib fractures sustained during blunt trauma occur infrequently. Patients should be instructed to seek immediate medical evaluation should they develop difficulty breathing, severe pain, or other concerning symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most rib fractures heal within six weeks. Many patients are able to resume daily activities much sooner. However, patients should be warned that pain from rib fractures can be severe for several days following the injury. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Analgesia and monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Routine follow-up chest x-rays days after the injury are not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/37\">",
"     37",
"    </a>",
"    ]. They add little besides cost to a careful clinical examination and should be performed only if indicated by clinical findings (eg, unilateral decreased breath sounds suggesting pneumothorax, persistent pain suggesting malunion or nonunion). A follow-up examination six to eight weeks after the injury is reasonable to assess the patient, if they are unable to return to sports or work by that time. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Return to sports and work'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND ASSOCIATED INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications from rib fractures correlate with the number of ribs fractured and fracture location. Associated injuries, such as liver or spleen lacerations, mediastinal injury, pneumothorax, hemothorax, flail chest, and pulmonary contusion, may occur, but are uncommon with isolated minor injuries. Complications associated with multiple rib fractures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link&amp;anchor=H68783394#H68783394\">",
"     \"Inpatient management of traumatic rib fractures\", section on 'Rib fracture complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link&amp;anchor=H18698528#H18698528\">",
"     \"Inpatient management of traumatic rib fractures\", section on 'Associated injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications, such as pneumonia, can occur as a result of atelectasis, caused by splinting from inadequate analgesia. In the elderly, morbidity and mortality are twice that in younger populations, and some increased morbidity is apparent in patients over 45 years old. Delayed complications (eg, pneumothorax, pulmonary contusion, pneumonia) occur, but are rare with minor injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/38\">",
"     38",
"    </a>",
"    ]. Rib fractures rarely go on to nonunion, and not all nonunions require surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link&amp;anchor=H886687#H886687\">",
"     \"Inpatient management of traumatic rib fractures\", section on 'Morbidity and mortality'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Indications for referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RETURN TO SPORTS AND WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return to work or sport depends upon the activity involved and the level of pain. Heavy labor and intensive training for athletes with stress fractures are not recommended for the first three weeks. When there is no pain at rest, the patient can begin to increase his or her activity level, but this should be done gradually. Most rib fractures heal within six weeks. Many patients are able to resume daily activities much sooner.",
"   </p>",
"   <p>",
"    Virtually all nonpathologic rib fractures heal well with conservative management. Some patients are able to return to work within a few days, depending on their occupation. One small case series suggests some patients experience prolonged pain and disability [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/39\">",
"     39",
"    </a>",
"    ]. It found that patients with an isolated rib fracture regain pain-free function at a mean of 51 days.",
"   </p>",
"   <p>",
"    Some athletes engaged in contact sports can return to play as soon as one week after acute injury, provided the fractured rib is protected with a flak jacket or similar device [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4376/abstract/40\">",
"     40",
"    </a>",
"    ]. The jacket should be worn for six to eight weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/53/41810?source=see_link\">",
"       \"Patient information: Rib fractures in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rib fractures are common injuries that occur most often following blunt thoracic trauma, but can also result from severe coughing, athletic activities (eg, rowing, swinging golf clubs), child abuse, and bone metastases. Concomitant injuries and complications range from mild discomfort to life-threatening conditions, such as pneumothorax, splenic laceration, and pneumonia. &nbsp;",
"     </li>",
"     <li>",
"      Rib fractures in victims of blunt trauma are generally identified clinically or by chest x-ray. Patients with rib fractures who have not sustained severe trauma typically describe a history of a minor to moderate chest wall injury. Frequently, they can localize the pain to one or two ribs and give a history that is consistent with the area of discomfort. Rib stress fractures present with a gradual onset of activity-related chest wall pain. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard posterior-anterior (PA) and lateral chest radiographs are adequate to identify most rib fractures. If these studies cannot be readily obtained, a simple anterior-posterior (AP) chest radiograph can provide useful information. A skeletal survey should be obtained in infants suspected of being abused. Findings consistent with abuse include the presence of multiple rib fractures in various stages of healing. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Radiographs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"       \"Physical abuse in children: Diagnostic evaluation and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Emergent referral is needed when rib fractures are accompanied by other major injuries (such as pneumothorax, liver or spleen lacerations, and cardiac or pulmonary contusions), or when such injuries are suspected. Multiple rib fractures correlate more closely with serious intrathoracic and intraabdominal injuries. Fractures of superior ribs (numbers 1 to 3) reflect trauma involving significant force and the potential for injury to major vessels and lung parenchyma. Displaced fractures increase the risk of internal injury and delayed bleeding and generally warrant admission. We suggest hospitalization for patients with three or more rib fractures. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications for referral'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of rib fractures should be focused on early and adequate pain relief to avoid complications from splinting and atelectasis, primarily pneumonia. To provide analgesia, clinicians most often use nonsteroidal anti-inflammatory drugs (NSAIDs) with or without opioids. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rib stress fractures are treated similarly to other low-risk stress fractures. Treatment begins with restriction of the inciting activity for four to six weeks, followed by a gradual return to the activity as tolerated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"       \"Overview of stress fractures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Virtually all rib fractures heal well with conservative management. Follow-up chest x-rays are unnecessary, unless indicated by clinical symptoms (eg, new shortness of breath). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1314128\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gray's Anatomy, Standins, S (Eds), Elsevier, New York 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/2\">",
"      Love JC, Symes SA. Understanding rib fracture patterns: incomplete and buckle fractures. J Forensic Sci 2004; 49:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/3\">",
"      Coris EE, Higgins HW 2nd. First rib stress fractures in throwing athletes. Am J Sports Med 2005; 33:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/4\">",
"      Connolly LP, Connolly SA. Rib stress fractures. Clin Nucl Med 2004; 29:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/5\">",
"      Warden SJ, Gutschlag FR, Wajswelner H, Crossley KM. Aetiology of rib stress fractures in rowers. Sports Med 2002; 32:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/6\">",
"      Hanak V, Hartman TE, Ryu JH. Cough-induced rib fractures. Mayo Clin Proc 2005; 80:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/7\">",
"      De Maeseneer M, De Mey J, Debaere C, et al. Rib fractures induced by coughing: an unusual cause of acute chest pain. Am J Emerg Med 2000; 18:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/8\">",
"      Sinha AK, Kaeding CC, Wadley GM. Upper extremity stress fractures in athletes: clinical features of 44 cases. Clin J Sport Med 1999; 9:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/9\">",
"      Christiansen E, Kanstrup IL. Increased risk of stress fractures of the ribs in elite rowers. Scand J Med Sci Sports 1997; 7:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/10\">",
"      Karlson KA. Rib stress fractures in elite rowers. A case series and proposed mechanism. Am J Sports Med 1998; 26:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/11\">",
"      Lord MJ, Ha KI, Song KS. Stress fractures of the ribs in golfers. Am J Sports Med 1996; 24:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/12\">",
"      Sakellaridis T, Stamatelopoulos A, Andrianopoulos E, Kormas P. Isolated first rib fracture in athletes. Br J Sports Med 2004; 38:e5.",
"     </a>",
"    </li>",
"    <li>",
"     Eckstein, M, Henderson, S. Thoracic Tr. In: Rosen's Emergency Medicine: Concepts and Clinical Practice, 6th edition, Marx, JA, Hockberger, RS, Walls, RM (Eds), Mosby Elsevier, Philadelphia 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/14\">",
"      Easter A. Management of patients with multiple rib fractures. Am J Crit Care 2001; 10:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/15\">",
"      Sirmali M, T&uuml;r&uuml;t H, Top&ccedil;u S, et al. A comprehensive analysis of traumatic rib fractures: morbidity, mortality and management. Eur J Cardiothorac Surg 2003; 24:133.",
"     </a>",
"    </li>",
"    <li>",
"     Westcott, J, Davis, SD, Fleishon, H, et al. Rib fractures. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000; 215 Suppl:637. www.acr.org (Accessed on June 06, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/17\">",
"      Sears BW, Luchette FA, Esposito TJ, et al. Old fashion clinical judgment in the era of protocols: is mandatory chest X-ray necessary in injured patients? J Trauma 2005; 59:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/18\">",
"      Kiev J, Kerstein MD. Role of three hour roentgenogram of the chest in penetrating and nonpenetrating injuries of the chest. Surg Gynecol Obstet 1992; 175:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/19\">",
"      Simon BJ, Chu Q, Emhoff TA, et al. Delayed hemothorax after blunt thoracic trauma: an uncommon entity with significant morbidity. J Trauma 1998; 45:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/20\">",
"      Misthos P, Kakaris S, Sepsas E, et al. A prospective analysis of occult pneumothorax, delayed pneumothorax and delayed hemothorax after minor blunt thoracic trauma. Eur J Cardiothorac Surg 2004; 25:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/21\">",
"      Stawicki SP, Grossman MD, Hoey BA, et al. Rib fractures in the elderly: a marker of injury severity. J Am Geriatr Soc 2004; 52:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/22\">",
"      Bergeron E, Lavoie A, Clas D, et al. Elderly trauma patients with rib fractures are at greater risk of death and pneumonia. J Trauma 2003; 54:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/23\">",
"      Holcomb JB, McMullin NR, Kozar RA, et al. Morbidity from rib fractures increases after age 45. J Am Coll Surg 2003; 196:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/24\">",
"      Livingston DH, Shogan B, John P, Lavery RF. CT diagnosis of Rib fractures and the prediction of acute respiratory failure. J Trauma 2008; 64:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/25\">",
"      Holmes JF, Ngyuen H, Jacoby RC, et al. Do all patients with left costal margin injuries require radiographic evaluation for intraabdominal injury? Ann Emerg Med 2005; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/26\">",
"      Gupta A, Jamshidi M, Rubin JR. Traumatic first rib fracture: is angiography necessary? A review of 730 cases. Cardiovasc Surg 1997; 5:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/27\">",
"      Paik SH, Chung MJ, Park JS, et al. High-resolution sonography of the rib: can fracture and metastasis be differentiated? AJR Am J Roentgenol 2005; 184:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/28\">",
"      Hurley ME, Keye GD, Hamilton S. Is ultrasound really helpful in the detection of rib fractures? Injury 2004; 35:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/29\">",
"      Griffith JF, Rainer TH, Ching AS, et al. Sonography compared with radiography in revealing acute rib fracture. AJR Am J Roentgenol 1999; 173:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/30\">",
"      Karmakar MK, Ho AM. Acute pain management of patients with multiple fractured ribs. J Trauma 2003; 54:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/31\">",
"      Middleton C. The causes and treatments of phantom limb pain. Nurs Times 2003; 99:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/32\">",
"      Bulger EM, Edwards T, Klotz P, Jurkovich GJ. Epidural analgesia improves outcome after multiple rib fractures. Surgery 2004; 136:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/33\">",
"      Lazcano A, Dougherty JM, Kruger M. Use of rib belts in acute rib fractures. Am J Emerg Med 1989; 7:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/34\">",
"      Quick G. A randomized clinical trial of rib belts for simple fractures. Am J Emerg Med 1990; 8:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/35\">",
"      Ashrafian H, Kumar P, Sarkar PK, DeSouza A. Delayed penetrating intrathoracic injury from multiple rib fractures. J Trauma 2005; 58:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/36\">",
"      Iyoda A, Satoh N, Yamakawa H, et al. Rupture of the descending thoracic aorta caused by blunt chest trauma: report of a case. Surg Today 2003; 33:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/37\">",
"      Bansidhar BJ, Lagares-Garcia JA, Miller SL. Clinical rib fractures: are follow-up chest X-rays a waste of resources? Am Surg 2002; 68:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/38\">",
"      Dwyer MK, Uhl TL. A traumatic pneumothorax as a result of a rib fracture in a college baseball player. Orthopedics 2003; 26:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4376/abstract/39\">",
"      Kerr-Valentic MA, Arthur M, Mullins RJ, et al. Rib fracture pain and disability: can we do better? J Trauma 2003; 54:1058.",
"     </a>",
"    </li>",
"    <li>",
"     DeLee and Drez's Orthopaedic Sports Medicine: Principles and Practice, 2nd edition, DeLee, JC, Drez, D Jr., Miller, MD (Eds), Saunders, Philadelphia.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 246 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4376=[""].join("\n");
var outline_f4_17_4376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RELEVANT ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RADIOGRAPHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging following trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Analgesia and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMPLICATIONS AND ASSOCIATED INJURIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RETURN TO SPORTS AND WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1314128\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/246\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/246|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/14/24803\" title=\"diagnostic image 1\">",
"      Chest x-ray nondisplaced posterior rib fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/55/22385\" title=\"diagnostic image 2\">",
"      Chest x-ray rib fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/28/33217\" title=\"diagnostic image 3\">",
"      Portable chest x-ray rib fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/37/18006\" title=\"diagnostic image 4\">",
"      CT scan rib fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/41/25246\" title=\"diagnostic image 5\">",
"      Rib stress fracture bone scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/246|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/39/19064\" title=\"figure 1\">",
"      Rib and chest anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/7/17528\" title=\"figure 2\">",
"      Rib anatomy and external landmarks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/19/23857\" title=\"figure 3\">",
"      Flail chest",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=related_link\">",
"      Inpatient management of traumatic rib fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/53/41810?source=related_link\">",
"      Patient information: Rib fractures in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_17_4377="Lichtenstein hernia repair";
var content_f4_17_4377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Lichtenstein hernia repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 720px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The upper&nbsp;illustrations depict the relationship of the&nbsp;mesh to the floor of the inguinal canal&nbsp;(A,B).&nbsp;A tangential view (C) of the mesh shows the inversion of a direct hernia sac with a purse string suture and the overlying attenuated transversalis fascia in Hasselbach&rsquo;s triangle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4377=[""].join("\n");
var outline_f4_17_4377=null;
var title_f4_17_4378="Treatment of hairy cell leukemia";
var content_f4_17_4378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hairy cell leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/17/4378/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/17/4378/contributors\">",
"     Martin S Tallman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/17/4378/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/17/4378/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/17/4378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/17/4378/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/17/4378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hairy cell leukemia (HCL) is an uncommon chronic B cell lymphoproliferative disorder. Its name is derived from the prominent irregular cytoplasmic projections of the malignant cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The treatment of HCL will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The pathophysiology, clinical manifestations, and diagnosis of this disorder are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=see_link\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with HCL are asymptomatic and can be observed for months or years after the diagnosis is established before requiring treatment. There is no clear advantage to early treatment; therapy is indicated only when the patient develops one or more of the following problems or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/5\">",
"     5",
"    </a>",
"    ]. There is a theoretic risk of infection in such patients, occasionally with opportunistic organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\", section on 'Presenting complaints'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant cytopenias; typical peripheral blood counts that warrant treatment include an absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;1000/microL",
"      </span>",
"      with repeated infections, symptomatic anemia with a hemoglobin concentration &lt;11.0",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      or bleeding due to a platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Symptomatic splenomegaly (common) or symptomatic adenopathy (uncommon)",
"     </li>",
"     <li>",
"      Constitutional symptoms (eg, fever, night sweats, fatigue, weight loss)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of interest, in a long-term follow-up study of 233 patients with hairy cell leukemia, those with a hemoglobin concentration &lt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a platelet count",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL",
"    </span>",
"    at the start of treatment had a significantly shorter median relapse-free survival after treatment with a purine analog than did those without such findings (9 versus 20+ years, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with HCL may be at increased risk of developing infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of treatment options are available for patients with symptomatic HCL, including splenectomy, interferon, and cytotoxic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/10\">",
"     10",
"    </a>",
"    ]. If therapy is indicated, the purine analogs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    have replaced splenectomy and interferon as initial agents of choice. Because of ease of administration, a single cycle of cladribine may be the preferred choice (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Choice of purine analog'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Purine analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purine analogs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    (2'-deoxycoformycin, 2'-DCF) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    (2-chlorodeoxyadenosine, 2-CdA) are naturally targeted to lymphocytes and are cytotoxic to both resting and dividing cells. Both drugs induce durable complete remissions (CRs) in the overwhelming majority of patients with HCL. Equally high rates of durable CRs are achieved with these two agents in both untreated and previously treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/9,11\">",
"     9,11",
"    </a>",
"    ], and those with large or minimal tumor burdens. For these reasons, these agents have emerged as the treatments of choice for all patients with HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. There are no large series of patients with HCL treated with the other major purine analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    . Initial reports suggest that purine analogs may be safely combined with monoclonal antibodies, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , resulting in high response rates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Anti-CD20 antibody (rituximab)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cladribine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     Cladribine",
"    </a>",
"    (2-CdA) is a purine analog that does not inhibit ADA, as does",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    , and is resistant to its action. Cladribine accumulates in lymphoid cells presumably because they are rich in deoxycytidine kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/14\">",
"     14",
"    </a>",
"    ]. This enzyme phosphorylates cladribine, creating a deoxynucleotide that cannot readily exit the cell. The net effect is lymphotoxicity analogous to that seen in ADA-deficient children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     Cladribine",
"    </a>",
"    was first reported to be effective for HCL in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/16\">",
"     16",
"    </a>",
"    ]. Twelve patients were treated with a single cycle of cladribine (0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day by continuous infusion for 7 days) and a complete pathologic remission was obtained in 11 within 8 weeks of treatment. None of the patients had relapsed after a median follow-up of 16 months. No patients experienced the usual toxicities of cytotoxic chemotherapy (ie, nausea, emesis, alopecia, or other constitutional symptoms).",
"   </p>",
"   <p>",
"    The standard regimen is a 7-day continuous intravenous infusion program (0.10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. Alternative routes and schedules of administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    have included five-day two-hour infusion at a dose of 0.14",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], weekly two-hour infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], subcutaneous administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/23,24,28\">",
"     23,24,28",
"    </a>",
"    ], and oral administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/23,24,29\">",
"     23,24,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest series of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    therapy in HCL provided outcome data on 861 evaluable patients through the group C protocol mechanism from the National Cancer Institute [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/22\">",
"     22",
"    </a>",
"    ]. The complete remission rate was 50 percent, considerably less than in other reports; 4-year disease-free survival was 84 percent. There was no central pathology review for these subjects, who may have had other indolent lymphoproliferative disorders.",
"   </p>",
"   <p>",
"    The largest single institution experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 7 days by continuous intravenous infusion) consisted of 349 evaluable patients with previously treated or untreated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The complete and partial remission rates were 91 and 7 percent, respectively. At four years, the overall survival was 96 percent; the relapse rates for patients achieving CR and PR were 16 and 54 percent, respectively. Of the 53 patients in first relapse after a cladribine-induced remission, retreatment with cladribine yielded CR and PR rates of 62 and 26 percent, respectively.",
"   </p>",
"   <p>",
"    In other studies, including our own, 76 to 80 percent of assessable patients with HCL treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    achieved CR and 7 to 24 percent achieved PR, with minimal toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/9,17,18,30\">",
"     9,17,18,30",
"    </a>",
"    ]. The majority of patients remained disease-free for a prolonged period of time, with relapse rates of 14 to 20 percent at 24 to 30 months and 36 percent at 9.7 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/30\">",
"     30",
"    </a>",
"    ]. Progression-free survival and overall survival at four years have been 72 to 84 percent and 86 to 96 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/17,19-21,31,32\">",
"     17,19-21,31,32",
"    </a>",
"    ]. Overall survival in two series, including our own, was 79 to 87 percent after 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/30,33\">",
"     30,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever occurs in about 40 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    , coinciding with a rapid decline in the number of circulating hairy cells and neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/34\">",
"     34",
"    </a>",
"    ]. In some series, no viral, fungal, or other opportunistic infections were observed other than a single case of dermatomal herpes zoster 16 months after treatment. Infections are rarely documented, and it is believed that the fever may reflect cytokine release from hairy cells.",
"   </p>",
"   <p>",
"    To explore the relationship between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    -induced fever and neutropenia, a phase II trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day SQ on days -3, -2, and -1, and again after the completion of cladribine) was initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/34\">",
"     34",
"    </a>",
"    ]. Treatment with G-CSF shortened the period of neutropenia, as compared with historical controls treated with cladribine alone. However, the incidence of febrile patients, number of febrile days, or frequency of admission for treatment with antibiotics was not changed.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     Cladribine",
"    </a>",
"    therapy may be associated with the development of unexpected foci of hypoplasia and aplasia in bone marrow biopsies performed as part of their evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/35\">",
"     35",
"    </a>",
"    ]. These foci are present in patients in CR with normal peripheral blood counts; their long-term significance is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pentostatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     Pentostatin",
"    </a>",
"    was the first drug reported which induced a high rate of complete remissions in HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. It is an irreversible inhibitor of adenosine deaminase (ADA) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/15\">",
"     15",
"    </a>",
"    ], an enzyme critical to purine metabolism found in all lymphoid cells. Deoxyadenosine triphosphate metabolites accumulate within hairy cells after treatment with pentostatin and are thought to be responsible for the cytotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/14,38\">",
"     14,38",
"    </a>",
"    ]. The dose of pentostatin approved by the US Food and Drug Administration for the treatment of HCL is 4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every two weeks until maximal response.",
"   </p>",
"   <p>",
"    A number of studies have been published using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    in a variety of different doses and schedules [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/29,36,37,39-47\">",
"     29,36,37,39-47",
"    </a>",
"    ]. In an Eastern Cooperative Oncology Group (ECOG) study, 50 patients with HCL were treated with pentostatin (5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day intravenously (IV) for two consecutive days every two weeks until maximum response) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/40\">",
"     40",
"    </a>",
"    ]. The overall response rate and complete remission rate were 84 and 64 percent, respectively, with the majority of patients achieving maximal response within six months.",
"   </p>",
"   <p>",
"    Toxicities were moderate and included nausea, vomiting, skin rash and conjunctivitis, as well as significant neurologic toxicities in four patients. Neutropenia was \"life-threatening\" in 70 percent of patients; however, this was limited to the first two to three cycles of therapy. Mortality as a result of therapy was attributable to infection in 6 percent of patients.",
"   </p>",
"   <p>",
"    Other investigators have administered a lower dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    and have produced similar results with reduced toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/29,46\">",
"     29,46",
"    </a>",
"    ]. In one study, for example, patients were treated with pentostatin at a dose of 4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV every other week; complete remission was attained in 20 of 23 patients (87 percent) with infrequent infections and no treatment-related deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/29\">",
"     29",
"    </a>",
"    ]. CD4 positive cells were significantly, but only temporarily, decreased after treatment, with no opportunistic infections or second malignancies being noted after two years of follow-up.",
"   </p>",
"   <p>",
"    Another series evaluated a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    at 4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV weekly for three consecutive weeks, with therapy repeated every eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/46\">",
"     46",
"    </a>",
"    ]. Complete remission was achieved in 25 of 28 patients (89 percent) after completion of two cycles of therapy. Transient neutropenia occurred only during the first cycle and 12 patients developed fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection; there were no deaths.",
"   </p>",
"   <p>",
"    The relative efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    and IFNa was evaluated in a prospective intergroup study which randomly assigned 313 patients with HCL to receive either pentostatin (4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV every two weeks for six months) or IFNa (three million units SQ three times per week) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/44\">",
"     44",
"    </a>",
"    ]. Pentostatin therapy was associated with higher rates of confirmed complete remission (76 versus 11 percent) and confirmed complete or partial remission (79 versus 38 percent). Estimated overall and relapse-free survival of patients achieving CR with pentostatin were 87 and 76 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/48\">",
"     48",
"    </a>",
"    ]. Factors predictive of CR with pentostatin were high hemoglobin concentration, young age, and little or no splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a median follow-up of over 9 years, 83 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    on this protocol were still alive, and only 18 percent of those who achieved CR have relapsed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/48\">",
"     48",
"    </a>",
"    ]. Of the 40 deaths, only two were related to HCL; the standard mortality rate for the cohort of pentostatin-treated patients, as compared with the 1990 age- and sex-specific mortality for the white United States population was 1.05 (95 percent confidence limits: 0.75 to 1.43).",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    is usually effective in patients who are refractory to treatment with IFNa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Choice of purine analog",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with previously treated or untreated HCL achieve durable remissions with either multiple cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    or a single cycle of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/5,49\">",
"     5,49",
"    </a>",
"    ]. In one study of 233 patients followed for a median period of 16 years, overall response rates (100 versus 96 percent), rates of complete remission (76 versus 82 percent), and 10-year survivals (100 versus 96 percent) were similar for initial treatment with either cladribine or pentostatin, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. Patients achieving a complete response with either agent showed significantly longer median disease-free survival than those attaining only a partial remission (not reached at 14 years versus 5.5 years).",
"   </p>",
"   <p>",
"    Although these outcomes with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    are excellent, the ease of administration of a single cycle of cladribine and the paucity of toxicities with cladribine are attractive advantages. However, it is not clear whether one or the other of these agents has a lesser risk of second malignancies (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Second malignancies'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    produce prolonged immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Pentostatin therapy is associated with a decrease in the total lymphocyte count, with a reduction in T-cells proportionately greater than that for B-cells or natural killer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/53\">",
"     53",
"    </a>",
"    ]. Absolute numbers of CD4+ and CD8+ cells fall to less than 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for at least six months after pentostatin is discontinued. In two studies, the median time to recovery of CD4+ cell counts following cessation of therapy was 54 months with pentostatin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/54\">",
"     54",
"    </a>",
"    ] and 40 months with cladribine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this degree of immunosuppression, opportunistic infections, other than an occasional case of herpes zoster, are uncommon unless purine analog treatment is associated with concomitant glucocorticoid exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/51\">",
"     51",
"    </a>",
"    ]. Prophylaxis against Pneumocystis carinii pneumonia may be reasonable if glucocorticoids are being given for a separate indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous large studies have confirmed the activity of interferon alfa (IFNa) in HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/50,55-61\">",
"     50,55-61",
"    </a>",
"    ]. The precise mechanism of action of IFNa is not known. HCL may involve a deficiency in the production of cytokines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    , granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-6, perhaps related to the characteristic monocytopenia. Treatment with IFN-alpha may upregulate their production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IFNa increases intracellular IL-6 in HCL and induces secretion of IL-6 from peripheral blood mononuclear cells from HCL patients, but not healthy donors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/62\">",
"     62",
"    </a>",
"    ]. Thus, the benefits of IFNa may result in part from the induction of hematopoietic growth factors within the leukemic cell population.",
"   </p>",
"   <p>",
"    IFNa is commonly administered at a dose of two million",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    subcutaneously three times a week for 12 to 18 months. This regimen produces a high overall response rate of 75 to 90 percent; however, the majority of patients achieve only partial remission (defined as normalization of all peripheral blood counts) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/59,61\">",
"     59,61",
"    </a>",
"    ]. Furthermore, the median failure-free survival after discontinuing IFNa ranges from 6 to 25 months in different series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/56,59,61,63\">",
"     56,59,61,63",
"    </a>",
"    ]. The risk of early relapse is increased in patients with more than 30 percent hairy cells in the bone marrow or a platelet count",
"    <span class=\"nowrap\">",
"     &lt;160,000/microL",
"    </span>",
"    at the end of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/63\">",
"     63",
"    </a>",
"    ]. Patients with HCL who express the CD5 antigen appear to respond poorly to IFNa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment outcome can be improved by long-term maintenance IFNa in patients who respond to initial therapy at a dose of three million IU subcutaneously given three times a week [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/50\">",
"     50",
"    </a>",
"    ]. In this report, 60 percent of patients sustained their initial response for a median of five years, 9 percent discontinued therapy early due to unacceptable neurologic toxicity, and only 13 percent stopped therapy because of progressive disease.",
"   </p>",
"   <p>",
"    Although treatment of HCL with IFNa results in normalization of the peripheral blood counts in most patients, \"true\" complete remissions are uncommon, since residual disease can be demonstrated in splenic tissue after splenectomy in complete responders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/65\">",
"     65",
"    </a>",
"    ]. Treatment with IFNa may rarely play a role in the following instances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients failing treatment with purine analogs [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with HCL and pancytopenia who are treated initially with IFNa to improve their counts may tolerate subsequent purine analog therapy with fewer infectious complications [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/68\">",
"       68",
"      </a>",
"      ]. However, this has not become routine practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common toxicities of IFNa include flu-like symptoms, anorexia and fatigue, nausea and vomiting, diarrhea, dry skin, peripheral neuropathies and central nervous system dysfunction, including depression or memory loss. Elevated serum aminotransferases are the most common laboratory abnormality other than myelosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of the spleen was the first effective therapy for HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Although splenectomy does not produce pathologic remissions, peripheral blood counts return to normal in approximately 40 to 70 percent of patients, particularly those with a hairy cell index of 0.7 or less [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/69\">",
"     69",
"    </a>",
"    ]. The hairy cell index is defined as the cellularity of the bone marrow core biopsy specimen (stated as a fraction) multiplied by the fraction of hairy cells present in the cellular portion of the bone marrow core biopsy specimen.",
"   </p>",
"   <p>",
"    The response to splenectomy is maintained for a median of 20 months, approximately one-half have disease progression within five years, and the overall survival at five years is 60 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/69,72\">",
"     69,72",
"    </a>",
"    ]. Possible indications for splenectomy in HCL include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptomatic splenomegaly (massive enlargement, pain, infarction, rupture)",
"     </li>",
"     <li>",
"      Pancytopenia which is still present after other treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/73\">",
"       73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      As a temporizing measure in symptomatic pregnant women [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Highly effective therapy with purine analogs generally obviates the need for splenectomy in other settings (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Purine analogs'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Residual disease post-treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that cell proliferation in HCL is regulated by growth factors and cytokines, such as tumor necrosis factor (TNF)-alpha and interleukins (IL), and that serum levels of the TNF and IL family may be used as sensitive markers for monitoring disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/75\">",
"     75",
"    </a>",
"    ]. In a retrospective study in eight patients with relapsed HCL, a doubling of serial soluble IL-2 receptor levels was noted at a mean of 17 months before the onset of neutropenia and subsequent clinical relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The remarkable activity of the purine analogs has led to the examination of posttreatment bone marrow biopsies to detect minimal residual disease (MRD) in patients otherwise in CR. Immunohistochemistry using anti-CD20 antibodies in paraffin embedded biopsies is one technique used to identify MRD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/77-82\">",
"     77-82",
"    </a>",
"    ]. Depending upon the criteria used, 13 to 53 percent of patients in apparent CR have evidence of MRD, which may or may not predict future relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/77,78,80,83\">",
"     77,78,80,83",
"    </a>",
"    ]. However, molecular studies using polymerase chain reaction suggest that the malignant clone of cells may remain in patients in apparent morphologic remission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/84,85\">",
"     84,85",
"    </a>",
"    ] or even in apparent molecular remission using flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although MRD-negative status has been achieved in patients with hairy cell leukemia using sequential",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , it is not known yet whether this strategy will lead to long-term disease-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT OF RESISTANT OR RELAPSED DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall and complete response rates to initial treatment with purine analogs are approximately 96 to 100 and 80 percent, respectively, meaning that up to 4 percent of patients obtain no initial benefit and up to 20 percent achieve only a partial remission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/9,11,30,49\">",
"     9,11,30,49",
"    </a>",
"    ]. The suggested therapeutic option in such patients is use of a different purine analog from the one initially chosen. Other options include IFNa, splenectomy, or one of the available monoclonal antibodies directed against B-cell determinants on the malignant cell. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Monoclonal antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Variant hairy cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with HCL variants are poorly responsive or resistant to standard treatment (ie, splenectomy, interferon, purine analogs) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. &nbsp;Although treatment data are sparse, patients with variant HCL are candidates for treatment with monoclonal antibodies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , BL-22,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Relapsed disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since appreciable numbers of patients relapse after initial treatment, especially those attaining only a partial remission, developing a salvage treatment approach is important [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/91\">",
"     91",
"    </a>",
"    ]. As an example, in one long-term study the 10-year rates of relapse were 48 and 42 percent for subjects initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Choice of purine analog'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Retreatment with a second cycle of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    leads to a second complete remission in up to 70 percent of patients, and is the recommended approach [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/9,11,17,19,30\">",
"     9,11,17,19,30",
"    </a>",
"    ]. In one study, the probability of achieving a complete remission was not affected by whether the patient was retreated with the same purine analog (71 percent) or switched to the alternative one (68 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While overall response rates are 97 to 100 percent after second- and third-line treatment with the purine analogs, the rates of complete remission as well as the lengths of disease-free survival become progressively shorter with each course of therapy. In one study, disease-free survivals after first, second, and third-line treatment with purine analogs were \"not reached after 14 years\", 7.5, and 4 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with resistant or relapsed disease respond to treatment with IFNa, although relapse is common when therapy is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three monoclonal antibodies, directed against CD22, CD20, or CD25, have been evaluated in the treatment of resistant or relapsed HCL. These agents appear to be highly active and well tolerated even in patients resistant to treatment with the purine analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/92\">",
"     92",
"    </a>",
"    ]. However, all must be considered experimental at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Anti-CD20 antibody (rituximab)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has been evaluated in patients with",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    hairy cell leukemia. It may be useful in some patients who have failed at least two courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    although this is a \"non-approved\" indication for its use. The use of rituximab has yielded mixed results in clinical trials. Toxicity in all of these trials has been minimal. The following is an overview of some of the studies that have evaluated this treatment approach.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase 2 study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 24 patients with relapsed disease after treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      demonstrated overall response rates of 24 percent (3 complete, 3 partial) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of small studies have reported higher overall (64 to 100 percent) and complete (53 to 92 percent) responses, as well as overall molecular response rates as high as 70 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/9,85,94-96\">",
"       9,85,94-96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective review evaluated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      combined concurrently or sequentially with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      as second-line therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/97\">",
"       97",
"      </a>",
"      ]. All eight patients responded to therapy with seven complete responses. At a median follow-up of 29 months, only one patient had developed recurrent disease. The relative benefits of concurrent or sequential cladribine followed by rituximab will require further study.",
"     </li>",
"     <li>",
"      A retrospective review of 15 patients with relapsed or refractory HCL treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      reported disease response in all evaluable patients (13 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/98\">",
"       98",
"      </a>",
"      ]. Three patients achieved minimal residual disease negativity. After a median follow-up of 35 months, 14 patients remain progression-free, while one succumbed to complications of the disease. It is not clear that fludarabine provided additional benefit to the rituximab therapy.",
"     </li>",
"     <li>",
"      A phase 2 trial evaluated five days of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      followed approximately one month later with eight weekly treatments of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 36 patients with",
"      <strong>",
"       newly diagnosed",
"      </strong>",
"      HCL requiring treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/13\">",
"       13",
"      </a>",
"      ]. There were no severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      events and all patients achieved a complete response. After a median follow-up of 25 months, the median progression-free and overall survival durations had not been reached. It is not clear if overall survival is improved with the addition of rituximab following cladribine as compared with cladribine alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Anti-CD22 antibody (BL22)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial trials of the pseudomonas exotoxin-linked recombinant anti-CD22 antibody (BL22) have shown high response rates in patients with previously treated HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/99-102\">",
"     99-102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a phase II trial in 36 patients with",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    HCL who required treatment because of cytopenias, complete and overall responses were obtained in 25 and 50 percent, respectively, after one cycle of treatment and in 47 and 72 percent, respectively, after retreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/102\">",
"     102",
"    </a>",
"    ]. Complete and overall responses were highest (64 and 95 percent, respectively) in patients without massive splenomegaly or prior splenectomy, and were 21 and 36 percent, respectively, for those with a prior splenectomy or massive splenomegaly.",
"   </p>",
"   <p>",
"    Toxicities of BL22 have included reversible hemolytic uremic syndrome (HUS), a cytokine-release syndrome (fever, hypotension, myalgia or arthralgia), transient hypoalbuminemia, and elevated aminotransferase levels, and the presence of neutralizing antibodies in some patients, which prevented re-treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/102\">",
"     102",
"    </a>",
"    ]. When routinely available, BL22 will likely become the treatment of choice for patients who have relapsed or who are refractory to treatment with purine analogs.",
"   </p>",
"   <p>",
"    A second generation recombinant immunotoxin, CAT-8015, is closely related to BL22, from which it differs by three amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/103\">",
"     103",
"    </a>",
"    ]. This change appears to improve its binding affinity to CD22, resulting in better cytotoxic activity against B-cell cancer cell lines and malignant cells isolated from patients with HCL. Clinical trials of this agent are underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Anti-CD25 antibody (LMB-2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recombinant anti-CD25 antibody linked to a truncated form of pseudomonas exotoxin (LMB-2) has been used in phase I trials in patients with HCL who had experienced treatment failure with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    and IFNa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. Major responses were seen in these studies, with maximum reduction of malignant cells in the peripheral blood varying from 98 to 99.8 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10318036\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Many agents are under active investigation or in development. These include combinations of agents already used in HCL, agents approved for other diseases (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/106\">",
"     106",
"    </a>",
"    ]), novel monoclonal antibodies (eg, LMB-2, BL-22), and other novel agents. Some of these are described in the sections above. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Monoclonal antibodies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SECOND MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on the risk of second malignancies following therapy for HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/48,107-112\">",
"     48,107-112",
"    </a>",
"    ]. The range of findings can be illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 117 patients with HCL, there were 44 second malignancies in 36 patients; the majority being nonhematologic [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/109\">",
"       109",
"      </a>",
"      ]. Ninety percent confidence intervals for the relative risk of second malignancies varied widely, being 0.2 to 3.8 for splenectomy, 0.6 to 5.7 for purine analogs, 1.6 to 4.3 for interferon followed by purine analogs, and 1.6 to 8.4 for interferon alone.",
"     </li>",
"     <li>",
"      In 358 patients with HCL treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      , second malignancies, only one of which was hematologic, were noted in 8 percent (observed-to-expected ratio (OER) 1.9; 95 % CI 1.2-2.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. A similar OER for second malignancies of 1.5 for cladribine and 1.4 for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      was noted in another series of more than 1300 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/110\">",
"       110",
"      </a>",
"      ]. These ratios are similar to those reported in HCL before the purine analog era [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Italian Cooperative Group for the Study of Hairy Cell Leukemia observed a cumulative risk for development of a second malignancy of 14 percent at 15 years, similar to the expected rate (standard incidence ratio [SIR] of 1.01) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/111\">",
"       111",
"      </a>",
"      ]. However, the SIR for non-Hodgkin lymphoma was higher than expected, at 5.3. Use of interferon did not affect the incidence of second malignancies in this group.",
"     </li>",
"     <li>",
"      Data on 3104 patients with HCL reported to 16 population-based registries in the SEER Program indicated a statistically increased incidence of second cancers compared with the general population (SIR 1.2; 95% CI 1.1-1.4), especially for Hodgkin lymphoma (SIR 6.6), non-Hodgkin lymphoma (SIR 5.0), and thyroid cancer (SIR 3.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/112\">",
"       112",
"      </a>",
"      ]. The cumulative probability of all second cancers was 32 percent at 25 years following the diagnosis of HCL. It was estimated that, among 1000 HCL patients, a total excess of 3.4 cancers might be observed per year (ie,",
"      <span class=\"nowrap\">",
"       34/10,000).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     QUALITY OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to address the issue of quality of life in patients, a questionnaire was sent to individuals with a prior diagnosis of hairy cell leukemia who had been treated by this author [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/113\">",
"     113",
"    </a>",
"    ]. There was a 61 percent response rate, with the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lifestyle changes were noted by 40 to 60 percent of respondents (eg, more frequent exercise, healthier diets, a greater appreciation of life, loved ones, and physical health).",
"     </li>",
"     <li>",
"      More than 60 percent paid for some aspect of medical care in spite of having health insurance coverage at the time of diagnosis.",
"     </li>",
"     <li>",
"      Twelve percent could not obtain health insurance following treatment.",
"     </li>",
"     <li>",
"      Ten of 13 subjects had difficulty obtaining a life insurance policy or were denied coverage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hairy Cell Leukemia Research Foundation is a non-profit, all volunteer, patient run organization whose primary goal is to provide support and information concerning this disease and its treatment. Information about this Foundation can be found at:",
"    <a class=\"external\" href=\"file://www.hairycellleukemia.org/\">",
"     www.hairycellleukemia.org",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/17/4378/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/12/13506?source=see_link\">",
"       \"Patient information: Hairy cell leukemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with hairy cell leukemia (HCL) are asymptomatic and can be observed for months and occasionally years after the diagnosis is established before requiring treatment. There is no clear advantage to early therapy. As the goal of treatment is alleviation of symptoms and cytopenias, we believe that asymptomatic patients with HCL should not be treated. There is a theoretic risk of infection in such patients, occasionally with opportunistic organisms.",
"   </p>",
"   <p>",
"    Indications for treatment include (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications for treatment'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant cytopenias; typical peripheral blood counts that warrant treatment include an absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;1000/microL",
"      </span>",
"      with repeated infections, symptomatic anemia with a hemoglobin concentration &lt;11.0",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      or bleeding due to a platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Symptomatic splenomegaly (common) or adenopathy (uncommon)",
"     </li>",
"     <li>",
"      Constitutional symptoms (eg, fever, night sweats, fatigue, weight loss)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom treatment is indicated, we recommend a purine analog as first line therapy (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). Because of ease of administration, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Choice of purine analog'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A single cycle of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    (a seven-day continuous intravenous infusion program at a dose of 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) is most commonly used as initial therapy. Alternative outpatient treatment schedules may be equally effective. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cladribine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Resistant or relapsed disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resistant disease &mdash; For patients who do not respond to initial therapy with a purine analog, we recommend switching to an alternative purine analog (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Resistant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relapsed disease &mdash; For patients who relapse after initial therapy, we recommend repeat treatment with a purine analog over use of other modalities (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       Cladribine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      are equally effective in this setting, leading to a second complete remission in approximately 70 percent of patients and a third complete remission in approximately 50 percent. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Relapsed disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disease resistant to purine analog therapy &mdash; While it is not clear if there are any potentially curative treatment regimens for patients with HCL who are clearly resistant to purine analog therapy, the immunoconjugate BL22 appears particularly promising and is the treatment of choice if available.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      is a reasonable alternative. Participation in a properly conducted randomized trial is always an excellent option for such patients.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/1\">",
"      BOURONCLE BA, WISEMAN BK, DOAN CA. Leukemic reticuloendotheliosis. Blood 1958; 13:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/2\">",
"      Labouyrie E, Marit G, Vial JP, et al. Intrasinusoidal bone marrow involvement by splenic lymphoma with villous lymphocytes: a helpful immunohistologic feature. Mod Pathol 1997; 10:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/3\">",
"      Golomb HM. Hairy cell leukemia: treatment successes in the past 25 years. J Clin Oncol 2008; 26:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/4\">",
"      Cannon T, Mobarek D, Wegge J, Tabbara IA. Hairy cell leukemia: current concepts. Cancer Invest 2008; 26:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/5\">",
"      Grever MR. How I treat hairy cell leukemia. Blood 2010; 115:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/6\">",
"      Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma 2011; 52 Suppl 2:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/7\">",
"      Teodorescu M, Engebjerg MC, Johansen P, et al. Incidence, risk of infection and survival of hairy cell leukaemia in Denmark. Dan Med Bull 2010; 57:A4216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/8\">",
"      Damaj G, Kuhnowski F, Marolleau JP, et al. Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol 2009; 83:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/9\">",
"      Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/10\">",
"      Mey U, Strehl J, Gorschl&uuml;ter M, et al. Advances in the treatment of hairy-cell leukaemia. Lancet Oncol 2003; 4:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/11\">",
"      Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005; 104:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/12\">",
"      Jones G, Parry-Jones N, Wilkins B, et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 2012; 156:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/13\">",
"      Ravandi F, O'Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011; 118:3818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/14\">",
"      Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A 1980; 77:6865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/15\">",
"      Fox RM, Mann CJ, et al. Deoxyadenosine toxicity to human peripheral blood lymphocytes: Implications for 2-deoxyadenosine as a potential immunosuppressive drug. Cancer Treat Symposia 1984; 2:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/16\">",
"      Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/17\">",
"      Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1996; 88:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/18\">",
"      Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 1997; 15:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/19\">",
"      Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/20\">",
"      Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/21\">",
"      Lauria F, Rondelli D, Zinzani PL, et al. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Leukemia 1997; 11:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/22\">",
"      Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16:3007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/23\">",
"      Liliemark J, Albertioni F, Juliusson G, Eksborg S. A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration. Cancer Chemother Pharmacol 1996; 38:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/24\">",
"      Saven A, Cheung WK, Smith I, et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 1996; 14:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/25\">",
"      Robak T, Basiska-Morawiec M, Krykowski E, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1996; 22:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/26\">",
"      Lauria F, Bocchia M, Marotta G, et al. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999; 84:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/27\">",
"      Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007; 109:3672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/28\">",
"      Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/29\">",
"      Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/30\">",
"      Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005; 106:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/31\">",
"      Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994; 14 Suppl 1:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/32\">",
"      Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83:2906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/33\">",
"      Jehn U, Bartl R, Dietzfelbinger H, et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004; 18:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/34\">",
"      Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999; 93:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/35\">",
"      Siegel RS, Hakimian D, Spies W, et al. Technetium-99m sulfur colloid scanning and correlative magnetic resonance imaging in patients with hairy cell leukemia and hypocellular bone marrow biopsies after 2-chlorodeoxyadenosine. Leuk Lymphoma 1999; 35:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/36\">",
"      Johnston JB, Glazer RI, Pugh L, Israels LG. The treatment of hairy-cell leukaemia with 2'-deoxycoformycin. Br J Haematol 1986; 63:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/37\">",
"      Spiers AS, Moore D, Cassileth PA, et al. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). N Engl J Med 1987; 316:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/38\">",
"      Seto S, Carrera CJ, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985; 75:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/39\">",
"      Blick M, Lepe-Zuniga JL, Doig R, Quesada JR. Durable complete remissions after 2'-deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon alpha. Am J Hematol 1990; 33:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/40\">",
"      Cassileth PA, Cheuvart B, Spiers AS, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991; 9:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/41\">",
"      Catovsky D, Matutes E, Talavera JG, et al. Long term results with 2'deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 1994; 14 Suppl 1:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/42\">",
"      Dearden C, Catovsky D. Treatment of hairy cell leukemia with 2-deoxycoformycin. Leuk Lymphoma 1990; 1:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/43\">",
"      Golomb HM, Dodge R, Mick R, et al. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. Leukemia 1994; 8:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/44\">",
"      Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/45\">",
"      Ho AD, Thaler J, Mandelli F, et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1989; 7:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/46\">",
"      Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/47\">",
"      Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin. Blood 1994; 84:4061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/48\">",
"      Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/49\">",
"      Dearden CE, Matutes E, Hilditch BL, et al. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol 1999; 106:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/50\">",
"      Smith JW 2nd, Longo DL, Urba WJ, et al. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. Blood 1991; 78:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/51\">",
"      Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992; 79:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/52\">",
"      Steis RG, Urba WJ, Kopp WC, et al. Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients. J Natl Cancer Inst 1991; 83:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/53\">",
"      Urba WJ, Baseler MW, Kopp WC, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989; 73:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/54\">",
"      Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia 1997; 11:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/55\">",
"      Quesada JR, Reuben J, Manning JT, et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/56\">",
"      Berman E, Heller G, Kempin S, et al. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 1990; 75:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/57\">",
"      Flandrin G, Sigaux F, Castaigne S, et al. Treatment of hairy cell leukemia with recombinant alpha interferon: I. Quantitative study of bone marrow changes during the first months of treatment. Blood 1986; 67:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/58\">",
"      Golomb HM, Jacobs A, Fefer A, et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol 1986; 4:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/59\">",
"      Golomb HM, Ratain MJ, Fefer A, et al. Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia. J Natl Cancer Inst 1988; 80:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/60\">",
"      Quesada JR, Hersh EM, Manning J, et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986; 68:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/61\">",
"      Ratain MJ, Golomb HM, Vardiman JW, et al. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J Clin Oncol 1988; 6:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/62\">",
"      Schwarzmeier JD, Hilgarth M, Nguyen ST, et al. Inadequate production of hematopoietic growth factors in hairy cell leukemia: up-regulation of interleukin 6 by recombinant IFN-alpha in vitro. Cancer Res 1996; 56:4679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/63\">",
"      Ratain MJ, Golomb HM, Bardawil RG, et al. Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood 1987; 69:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/64\">",
"      Lauria F, Raspadori D, Foa R, et al. Reduced hematologic response to alpha-interferon therapy in patients with hairy cell leukemia showing a peculiar immunologic phenotype. Cancer 1990; 65:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/65\">",
"      Pangalis GA, Boussiotis VA, Kittas CH, et al. Hairy cell leukemia: Residual splenic disease after successful alpha interferon therapy. Leuk Lymph 1992; 6:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/66\">",
"      Seymour JF, Estey EH, Keating MJ, Kurzrock R. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 1995; 9:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/67\">",
"      Hoffman MA. Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases. Med Oncol 2011; 28:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/68\">",
"      Habermann TM, Andersen JW, Cassileth PA, et al. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol 1992; 80:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/69\">",
"      Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 1983; 61:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/70\">",
"      Jansen J, Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 1981; 47:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/71\">",
"      Van Norman AS, Nagorney DM, Martin JK, et al. Splenectomy for hairy cell leukemia. A clinical review of 63 patients. Cancer 1986; 57:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/72\">",
"      Magee MJ, McKenzie S, Filippa DA, et al. Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer 1985; 56:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/73\">",
"      Polliack A, Dann EJ. Rapid massive splenic relapse of hairy cell leukemia (HCL) during bone marrow remission after 2-chlorodeoxyadenosine therapy: the spleen as a sanctuary site in HCL? Blood 1994; 84:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/74\">",
"      Stiles GM, Stanco LM, Saven A, Hoffmann KD. Splenectomy for hairy cell leukemia in pregnancy. J Perinatol 1998; 18:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/75\">",
"      Barak V, Nisman B, Polliack A. The tumor necrosis factor family and and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol 1999; 62:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/76\">",
"      Arun B, Curti BD, Longo DL, et al. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am 2000; 6:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/77\">",
"      Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84:4310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/78\">",
"      Hakimian D, Tallman MS, Kiley C, Peterson L. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1993; 82:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/79\">",
"      Hounieu H, Chittal SM, al Saati T, et al. Hairy cell leukemia. Diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DBA.44. Am J Clin Pathol 1992; 98:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/80\">",
"      Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/81\">",
"      Matutes E, Meeus P, McLennan K, Catovsky D. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. Br J Haematol 1997; 98:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/82\">",
"      Thaler J, Dietze O, Faber V, et al. Monoclonal antibody B-ly7: a sensitive marker for detection of minimal residual disease in hairy cell leukemia. Leukemia 1990; 4:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/83\">",
"      Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010; 115:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/84\">",
"      Filleul B, Delannoy A, Ferrant A, et al. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994; 8:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/85\">",
"      Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 2004; 73:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/86\">",
"      Arons E, Margulies I, Sorbara L, et al. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res 2006; 12:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/87\">",
"      Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006; 107:4658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/88\">",
"      Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006; 32:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/89\">",
"      Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009; 114:4687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/90\">",
"      Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011; 37:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/91\">",
"      Zinzani PL, Pellegrini C, Stefoni V, et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer 2010; 116:4788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/92\">",
"      Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma 2004; 45:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/93\">",
"      Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003; 102:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/94\">",
"      Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001; 115:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/95\">",
"      Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102:3906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/96\">",
"      Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haematol 2008; 143:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/97\">",
"      Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007; 110:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/98\">",
"      Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 2012; 119:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/99\">",
"      Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/100\">",
"      Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/101\">",
"      Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23:6719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/102\">",
"      Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009; 27:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/103\">",
"      Salvatore G, Beers R, Margulies I, et al. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002; 8:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/104\">",
"      Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/105\">",
"      Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). Clin Cancer Res 2000; 6:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/106\">",
"      Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/107\">",
"      Kampmeier P, Spielberger R, Dickstein J, et al. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood 1994; 83:2931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/108\">",
"      Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 1997; 15:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/109\">",
"      Au WY, Klasa RJ, Gallagher R, et al. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood 1998; 92:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/110\">",
"      Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/111\">",
"      Federico M, Zinzani PL, Frassoldati A, et al. Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol 2002; 20:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/112\">",
"      Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007; 99:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/17/4378/abstract/113\">",
"      Hounshell J, Tomori C, Newlin R, et al. Changes in finances, insurance, employment, and lifestyle among persons diagnosed with hairy cell leukemia. Oncologist 2001; 6:435.",
"     </a>",
"    </li>",
"    <li>",
"     www.histio.org (Accessed on June 10, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4535 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4378=[""].join("\n");
var outline_f4_17_4378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Purine analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cladribine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pentostatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Choice of purine analog",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Residual disease post-treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT OF RESISTANT OR RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Resistant disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Variant hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Relapsed disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Anti-CD20 antibody (rituximab)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Anti-CD22 antibody (BL22)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Anti-CD25 antibody (LMB-2)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10318036\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SECOND MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      QUALITY OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Resistant or relapsed disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/12/13506?source=related_link\">",
"      Patient information: Hairy cell leukemia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_17_4379="Toxic cyanide doses";
var content_f4_17_4379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Toxic cyanide doses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Route of Exposure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Toxic Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Inhalation",
"       </td>",
"       <td>",
"        100 ppm x 30 min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        300 ppm x 5 min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Oral",
"       </td>",
"       <td>",
"        50 mg (HCN)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 mg (KCN)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermal",
"       </td>",
"       <td>",
"        100 mg/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous",
"       </td>",
"       <td>",
"        5-10 &micro;g/ kg/ min x 3-10 hrs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4379=[""].join("\n");
var outline_f4_17_4379=null;
var title_f4_17_4380="Types trace minerals";
var content_f4_17_4380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Macro-, trace-, and ultra-trace minerals in man",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Macro-minerals",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Sodium",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Potassium",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Chloride",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Calcium",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Phosphate",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Magnesium",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Trace minerals",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Iron",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Zinc",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Copper",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Manganese",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Fluoride",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Ultra-trace minerals",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Arsenic",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Boron",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Chromium",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Iodine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Selenium",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Silicon",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Nickel",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Vanadium",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4380=[""].join("\n");
var outline_f4_17_4380=null;
var title_f4_17_4381="Safe food handling practices";
var content_f4_17_4381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for safe food handling to avoid microbial food-borne illness (food poisoning)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Purchase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not buy precooked food that is stored adjacent to raw food, even if stored on ice.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not buy canned goods that are dented, cracked, or have a bulging lid.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Storage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make sure meat and poultry products are refrigerated when purchased.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use plastic bags to keep drippings from packages of meat and fish from contact with other foods.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store perishable items in the refrigerator within one hour of purchase.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maintain home refrigerator temperature between 32 and 40&deg;F (0 and 4&deg;C) and freezer temperature at &le;0&deg;F (-18&deg;C).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Freeze meat and poultry that will not be cooked within 48 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Freeze tuna, bluefish, and mahi-mahi that will not be cooked within 24 hours; other fish can be stored in the refrigerator for 48 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not store eggs on the refrigerator door (warmest part of the refrigerator).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refrigerate cooked foods within two hours of preparation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Divide leftovers into small portions and store in shallow containers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reheat leftovers to 165&deg;F (74&deg;C).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wash hands with soap and water before food preparation and after handling raw meat, poultry, fish, and uncooked eggs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thaw frozen meats and fish in the refrigerator or microwave, not at room temperature.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marinate foods in the refrigerator, not at room temperature.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid contact of cooked foods with contaminated utensils, plates, or food preparation surfaces.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wash utensils, plates, and cutting surfaces with soap and water after contact with raw meat, poultry, fish, or eggs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid contact of juices from uncooked meat, poultry, or fish with cooked foods or foods that will be eaten raw.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoroughly wash all fresh fruits and vegetables.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid recipes using raw eggs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cooking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use a meat thermometer to monitor internal cooking temperatures; cook beef and lamb to an internal temperature of 145&deg;F (63&deg;C), pork and ground beef to 160&deg;F (71&deg;C), and poultry to 170 to 180&deg;F&nbsp;(77 to 82&deg;C).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cook eggs until the yolk begins to harden.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boil marinade from raw meat or fish before using it on cooked food.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Serving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serve cooked products on clean plates with clean utensils.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep hot foods at 140&deg;F (60&deg;C) and cold foods below 40&deg;F (4&deg;C).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Never leave foods at room temperature longer than two hours (one hour if the ambient temperature is &gt;90&deg;F (32&deg;C)).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use coolers and ice packs to transport perishable foods away from home.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4381=[""].join("\n");
var outline_f4_17_4381=null;
var title_f4_17_4382="11 beta hydroxylase deficiency";
var content_f4_17_4382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Synthetic defect in CYP11B1 (11-beta-hydroxylase) deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 253px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathways of adrenal steroid synthesis. A synthetic defect in 11-beta-hydroxylase leads to diminished cortisol synthesis, increased release of ACTH, and accumulation of 11- deoxycorticosterone (leading to mineralocorticoid excess), 11-deoxycortisol, and DHEA, androstenedione, and testosterone (leading to virilization). The numbers at the arrows refer to specific enzymes: 17 &alpha; = 17&alpha;-hydroxylase (P450c17); 17,20 = 17,20 lyase which is part of the P450c17 enzyme; 3&sect; = 3&sect;-hydroxysteroid dehydrogenase; 21 = 21-hydroxylase (P450c21); 11&beta; = 11&beta;-hydroxylase; (P450c11); 18 refers to the two-step process of aldosterone synthase (P450c11as), resulting in the addition of an hydroxyl group that is then oxidized to an aldehyde group at the 18-carbon position; ? = unclear if pathway functions in vivo; DHEA = dehydroepiandrostenedione; 17KSR = 17-ketosteroid reductase; and A = aromatase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4382=[""].join("\n");
var outline_f4_17_4382=null;
var title_f4_17_4383="Pleural liquid turnover";
var content_f4_17_4383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Pathways of pleural liquid turnover",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 308px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the pathways of normal pleural liquid turnover. Pleural liquid appears to originate from the systemic vessels of both the parietal and visceral pleural membranes (dashed arrows). The parietal vessels (intercostal microvessels) are thought to be of primary importance because they are closer to the pleural space and have a higher filtration pressure than the bronchial microvessels of the visceral pleura. Pleural liquid is initially partially reabsorbed by the microvessels; the remaining fluid exits the pleural space via the lymphatic stomata in the parietal pleura (solid arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_17_4383=[""].join("\n");
var outline_f4_17_4383=null;
